Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Genmab A/S

    NASDAQ: GMAB · Real-Time Price · USD
    24.16
    0.34 (1.43%)
    At close: Aug 20, 2025, 12:48 PM
    1.43%
    Bid 24.15
    Market Cap 15.24B
    Revenue (ttm) 22.32B
    Net Income (ttm) 6.71B
    EPS (ttm) 1.93
    PE Ratio (ttm) 12.52
    Forward PE 1.61
    Analyst Buy
    Ask 24.17
    Volume 590,669
    Avg. Volume (20D) 1,351,329.2
    Open 24.08
    Previous Close 23.82
    Day's Range 24.02 - 24.39
    52-Week Range 17.23 - 27.94
    Beta 0.80

    About GMAB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol GMAB
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for GMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Genmab A/S is scheduled to release its earnings on Nov 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    +5.49%
    Genmab shares are trading higher after the company... Unlock content with Pro Subscription
    1 month ago
    +3.4%
    Genmab shares are trading higher after the company reported Q2 net sales of DARZALEX totaling $3.539B.
    news image

    1 week ago · benzinga.com

    Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

    Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...

    news image

    1 week ago · zacks.com

    Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade

    The mean of analysts' price targets for Genmab (GMAB) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

    news image

    1 week ago · seekingalpha.com

    Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

    Genmab A/S (GMAB) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Anthony Pagano - Executive VP & CFO Brad Bailey - Corporate Participant Jan G.J. van de Winkel - Co-F...

    news image

    2 weeks ago · zacks.com

    GMAB vs. ACAD: Which Stock Is the Better Value Option?

    Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks off...

    2 weeks ago · youtube.com

    Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

    Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

    2 weeks ago · youtube.com

    President Trump demands drugmakers slash prices within 60 days

    CNBC's Joe Kernen reports on the latest news.

    news image

    4 weeks ago · zacks.com

    Genmab (GMAB) Upgraded to Strong Buy: Here's Why

    Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    news image

    4 weeks ago · zacks.com

    Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?

    The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in...

    news image

    1 month ago · seekingalpha.com

    Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One

    Genmab A/S is a high-margin, royalty-driven biotech with a robust pipeline and strong partnerships, notably with J&J, AbbVie, and Pfizer. Darzalex remains the key revenue driver, but patent protection...

    news image

    2 months ago · businesswire.com

    Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

    COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bisp...

    Add to Watchlist